|
Title
|
|
|
|
Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Aims We examined whether parenteral regular insulin can prevent diabetes in IA-2 antibody-positive (IA-2A+) relatives of type 1 diabetic patients, using a trial protocol that differed substantially from that of the Diabetes Prevention Trial-1. Methods Twenty-five IA-2A+ relatives received regular human insulin twice a day for 36 months, during which time they were followed (median [interquartile range; IQR]: 47 [1966] months) for glucose tolerance, HbA1c and islet autoantibodies, together with 25 IA-2A+ relatives (observation/control group) who fulfilled the same inclusion criteria, but were observed for 52 [2767] months (P = 0.58). Results Twelve (48%) insulin-treated relatives and 15 (60%) relatives in the control group developed diabetes. There was no difference in diabetes-free survival between the two groups (P = 0.97). Five-year progression (95% confidence interval) was 44% (2569) in the insulin-treated group and 49% (2970) in the observation group. At inclusion, progressors tended to have a higher pro-insulin/C-peptide ratio than non-progressors when measured 2 hours after a standardized glucose load (median [IQR]: 2.7% [1.84.3] vs. 1.6% [1.12.1]; P = 0.01). No major hypoglycaemic episodes or significant increases in body mass index or diabetes autoantibodies were observed. Conclusion Prophylactic injections of regular human insulin were well tolerated, but failed to prevent type 1 diabetes onset in IA-2A+ relatives. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Diabetes & metabolism. - Paris, 1996, currens
| |
|
Publication
|
|
|
|
Paris
:
2009
| |
|
ISSN
|
|
|
|
1262-3636
[print]
1878-1780
[online]
| |
|
Volume/pages
|
|
|
|
35
:4
(2009)
, p. 319-327
| |
|
ISI
|
|
|
|
000270775300010
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|